- Results of First Exposure of Type I Diabetes Patients to Oramed's OralInsulin and of a First-in-Humans Study With its Oral GLP-1 Analog
Advertisement
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that itsexecutive management is participating in the 2010 Scientific Sessions of theAmerican Diabetes Association currently being held in Orlando, Florida. Dr.Miriam Kidron, Chief Scientific Officer, is scheduled to present results oftwo of the company's recently completed clinical trials between 12:00 - 2:00PM ET on Monday, June 28, 2010 in Poster Hall C at the Orange CountyConvention Center.
Advertisement
One presentation will provide an overview of the results of a Phase IIastudy testing the company's flagship ORMD-0801 oral insulin capsule in Type Idiabetes patients when administered just before (10-90 minutes) a standardmeal. This first exposure of Oramed's oral insulin established the drug'ssafety and efficacy in Type I diabetics. ORMD-0801 led to a significantincrease in insulin levels in 61% of the treatment sessions, irrespective ofthe time lapse between ORMD-0801 administration and mealtime. The oralinsulin preparation effectively kept glucose levels in check in all sessions.These data suggest both tolerance of Oramed's platform to preprandial dosingregimens and its therapeutic potential in regulating Type I diabetes.
In addition, Dr. Kidron will present a summary of Oramed'sfirst-in-humans clinical trial testing the safety and efficacy of ORMD-0901,an encapsulated oral GLP-1 analog formulation. The study monitored theresponses of healthy males to a single dose delivered 60 minutes before aglucose load. ORMD-0901 was well tolerated by all subjects and demonstratedphysiological activity, as extrapolated from ensuing subject insulin levelswhen compared to those observed after treatment with placebo.
The poster entitled "Oral Insulin: Type I Diabetes (T1DM) PatientResponse Upon Preprandial Administration" will be featured in a guided tourin the Poster Hall. The tour title is "Innovations in Novel InsulinPreparations" and is scheduled for Monday June 28 at 12:00-1:00 PM.
To view the posters being presented, please visit: http://www.oramed.com
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inPhase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research performed by top research scientists at Jerusalem'sHadassah Medical Center. The Company's corporate and R&D headquarters arebased in Jerusalem.
For more information, please visit http://www.oramed.com.
Safe Harbor Statement
Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Company and Investor Relation Contacts: Oramed Pharmaceuticals Inc. Tara Horn Office: +1-646-240-4193 Cell: +972-54-334-4318 Email: [email protected]
SOURCE Oramed Pharmaceuticals Inc.
